Maryellen de Mars

Maryellen de Mars is MDIC’s program director, of clinical diagnostics. Maryellen oversees the clinical diagnostics program, encompassing projects that aim to improve diagnostic product development and validation using novel regulatory approaches to help drive innovation and access by patients.

Before joining MDIC, Dr. de Mars was the senior director of commercialization at Integrated Nano-Technologies, Inc. (INT), where she led efforts toward regulatory approval and market launch of a novel molecular platform for the detection of COVID-19. Before INT, Dr. de Mars was vice-president of the standards resource center (SRC) at ATCC, a business unit focused on standards and related services supporting life science research and development. While at ATCC, she served as an industry representative in early MDIC srs efforts to help mold and define the current project. Before ATCC, Dr. de Mars served as chief operating officer and vice president of clinical operations at USDS, Inc., an independent third party evaluating the performance of molecular diagnostic tests to support regulatory, reimbursement, and adoption efforts. She also served as director, of clinical biomarkers at Critical Path Institute (C-Path), leading collaborative efforts to evaluate and improve the utility of clinical biomarkers and optimize the pathway for the development of companion diagnostics. She served as executive director of genomics services at Gene Logic, Inc. as well as director of Gene Logic’s biorepository. Dr. de Mars led business development and marketing efforts for several product lines at Life Technologies, Inc., now ThermoFisher Scientific. Dr. de Mars holds a B.A. from Smith College and a Ph.D. in virology from the University of Texas. She completed postdoctoral training in transcriptional regulation at The Johns Hopkins University.

Email: mdemars@mdic.org